Overview

A major objective of NLST-ACRIN is the creation of a national resource of biospecimens consisting of serial collections of blood components (plasma and buffy coat), urine, and sputum from a subset of participants at each of the three annual NLST screening exams as well as resected tissues from trial participants with lung cancer. 

By coupling biospecimen collection with imaging-based screening, the NLST-ACRIN Biorepository is relatively enriched for early clinical stage lung cancers and associated biospecimens, and should provide a unique resource of extremely well characterized biospecimens with longitudinal data.  The NLST-ACRIN Biorepository is available for all research platforms that will validate biomarkers of early lung cancer that are proven to have potential in preliminary testing.   


NLST-ACRIN Biospecimen Research Opportunity [PDF]

ACRIN Data Sharing Policy and Biorepository Process

The NLST-ACRIN Biorepository is governed by the ACRIN Data Sharing Policy, which outlines ACRIN's data sharing process and summarizes what information ACRIN will release to requesters.


NLST-ACRIN Biorepository Application Review Process [PPT]

Data Sharing Policy  [Link]

Data Sharing Policy [DOC]


Requests Forms for NLST-ACRIN Biospecimens, Images and Clinical Data

Individuals interested in obtaining ACRIN-NLST biospecimens, images and/or clinical data for projects unrelated to ACRIN-NLST study aims described in the protocol (www.acrin.org/6654_protocol.aspx) should review the Biorepository Summary and complete the following form. 

Application for NLST-ACRIN Biospecimens [DOC]

Submission Deadlines

Applications will be accepted November 1, April 1, and August 1.